texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials

Debra Patt, M.D., M.P.H., M.B.A.


Debra Patt, M.D., M.P.H., M.B.A.

Provider Type: Physician

Specialties:

Locations:

General Summary:

Debra Patt, M.D., is a practicing oncologist and breast cancer specialist in Austin, Texas, and a vice president of Texas Oncology. She is an active leader in breast cancer research, serves on the US Oncology Research breast cancer committee, and chairs the breast cancer subsection of the pathways task force for The US Oncology Network.

She led healthcare informatics for The US Oncology Network from 2008-2015 and is the Editor-in-Chief of the Journal of Clinical Oncology-Clinical Cancer Informatics. She continues to lead the analytics group for McKesson Specialty Health. In addition to a substantial background in informatics and health economics and outcomes research, she directs public policy for Texas Oncology. Nationally she is the chair of ASCO’s clinical practice committee.

Dr. Patt serves on the national board for the Community Oncology Alliance and local boards of Komen Austin and The Shivers Cancer Foundation. She is a past chair for the Texas Medical Association’s committee on cancer and is active as a member of the council on legislation and committee on science and public health. Dr. Patt is a nationally recognized leader in cancer research, has published many articles, and leads the service line for breast health services for the Dell Medical School.

Credentials:

Dr. Patt completed her training in hematology and medical oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas, in July 2006. She completed her masters of public health at The University of Texas Health Science Center’s School of Public Health in Houston, Texas, in May 2006, where she focused on cancer health policy. She completed the Cancer Prevention Program as well at the National Cancer Institute in August 2005.

She received her medical degree in May 1999 from the Baylor College of Medicine in Houston, Texas. She completed her residency training in internal medicine and pediatrics from the Baylor College of Medicine in Houston, Texas, in July 2003. She completed her bachelor of science in zoology in May 1995 at The University of Texas in Austin where she graduated with special honors in the Plan I honors program. She also received her MBA from The University of Texas in Austin, Texas, in 2014.

Accolades & Memberships:

Dr. Patt completed the ASCO leadership development program in 2014. She was awarded the young physician of the year award in Travis County in 2014. She received the prestigious ASCO Young Investigator’s Award in June 2006. In July 2006 she was awarded the Fellow of the Year at The University of Texas MD Anderson Cancer Center in Research for her excellence in breast cancer research. In March 2006 she was awarded the Jesse H. Jones Fellowship in Cancer Education at The University of Texas MD Anderson Cancer Center.

Other Information:

Dr. Patt is married to Hanoch Patt, M.D., a pediatric cardiologist in Austin. They have three children.

Clinical Focus:

Videos:

Publications

  • Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors with Chemotherapy for Breast Cancer

    Journal of Clinical Oncology, 2016

  • Better Screening Using Big Data

    Journal of Oncology Practice, 2016

  • The treatment patterns, efficacy, and safety of nab-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis

    BMC Cancer, 2015

  • Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices

    Journal of the National Comprehensive Cancer Network, 2015

  • Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma

    Leukemia & Lymphoma, 2015

  • Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

    Journal of Clinical Oncology, 2015

  • Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline

    Journal of Clinical Oncology, 2014

  • Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

    Journal of Clinical Oncology, 2014

  • Taking on racial and ethnic disparities in cancer care

    Journal of Community and Supportive Oncology, 2014

  • Women in oncology

    American Society of Clinical Oncology, 2013

  • Oncology comparative effectiveness research: a multistakeholder perspective on principles for conduct and reporting

    Oncologist, 2013

  • Defining cancer care quality or delivering quality cancer care?

    Journal of the National Comprehensive Cancer Network, 2013

  • Evaluating Use Characteristics for the Oncotype DX 21-gene recurrence score and concordance with chemotherapy use in early stage breast cancer

    Journal of Oncology Practice, 2013

  • Evaluating Use Characteristics for the Oncotype Dx 21-Gene Recurrence Score and Concordance With Chemotherapy Use in Early-Stage Breast Cancer

    American Society of Clinical Oncology, 2013

  • A Structured Genetic Risk Evaluation and Testing Program in the Community Oncology Practice Increases Identification of Individuals at Risk for BRCA Mutations

    Compass Oncology, 2012

  • Thoughts and recommendations on cancer care site of service

    Community Oncology, 2012

  • Changes in adjuvant breast cancer chemotherapy regimen selection over time in the community

    JCO supplements, 2012

  • Utilization of pegfilgrastim in adjuvant chemotherapy regimens for breast cancer in the community

    JCO Supplements, 2011

  • Evaluating utilization characteristics for the Oncotype DX recurrence score in early-stage breast cancer

    JCO Supplements, 2011

  • Understanding male breast cancer in the community setting

    JCO Supplements, 2011

  • Utilization and relative value of breast cancer adjuvant chemotherapy regimens in the community

    JCO Supplements, 2011

  • Pathways, Outcomes, and Costs in Colon Cancer:  Retrospective evaluations in two distinct databases

    Journal of Oncology Practice, 2011

  • Iniparib plus Chemotherapy n Metastatic Triple-Negative Breast Cancer

    New England Journal of Medicine, 2011

  • Benchmarks for value in cancer care: an analysis of a large commercial population

    Journal of Oncology Practice, 2011

  • Randomized phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer

    Journal of Thoracic Oncology, 2010

  • Pilomatrical carcinosarcoma

    Otolaryngology-Head and Neck Surgery, 2010

  • Ixabepilone alone and in combination with chemotherapy in the community setting

    Proceedings ASCO Breast Cancer Symposium, 2010

  • Combination versus sequential chemotherapy for metastatic breast cancer: An evaluation of outcomes from a community oncology network

    Journal of Clinical Oncology, 2010

  • Acute Myeloid Leukemia after Adjuvant Breast Cancer Therapy in Older Women: Understanding Risk.

    Journal of Clinical Oncology, 2007

  • Paclitaxel in Breast Cancer.

    Women's Health, 2006

  • Cardiac morbidity of adjuvant radiotherapy in patients with early stage breast cancer

    Journal of Clinical Oncology, 2005

  • Trends to protect workers from job related secondhand smoke in Texas

    Texas Medicine, 2005